全文获取类型
收费全文 | 10271篇 |
免费 | 571篇 |
国内免费 | 43篇 |
专业分类
耳鼻咽喉 | 252篇 |
儿科学 | 338篇 |
妇产科学 | 134篇 |
基础医学 | 1545篇 |
口腔科学 | 327篇 |
临床医学 | 1035篇 |
内科学 | 1832篇 |
皮肤病学 | 223篇 |
神经病学 | 808篇 |
特种医学 | 482篇 |
外科学 | 1473篇 |
综合类 | 99篇 |
一般理论 | 9篇 |
预防医学 | 608篇 |
眼科学 | 396篇 |
药学 | 727篇 |
中国医学 | 20篇 |
肿瘤学 | 577篇 |
出版年
2022年 | 56篇 |
2021年 | 124篇 |
2020年 | 82篇 |
2019年 | 131篇 |
2018年 | 160篇 |
2017年 | 145篇 |
2016年 | 170篇 |
2015年 | 191篇 |
2014年 | 223篇 |
2013年 | 334篇 |
2012年 | 400篇 |
2011年 | 470篇 |
2010年 | 274篇 |
2009年 | 243篇 |
2008年 | 431篇 |
2007年 | 471篇 |
2006年 | 466篇 |
2005年 | 443篇 |
2004年 | 441篇 |
2003年 | 413篇 |
2002年 | 326篇 |
2001年 | 423篇 |
2000年 | 378篇 |
1999年 | 333篇 |
1998年 | 163篇 |
1997年 | 123篇 |
1996年 | 129篇 |
1995年 | 96篇 |
1994年 | 105篇 |
1993年 | 58篇 |
1992年 | 175篇 |
1991年 | 166篇 |
1990年 | 180篇 |
1989年 | 177篇 |
1988年 | 144篇 |
1987年 | 132篇 |
1986年 | 119篇 |
1985年 | 121篇 |
1984年 | 88篇 |
1983年 | 84篇 |
1982年 | 56篇 |
1981年 | 55篇 |
1980年 | 58篇 |
1979年 | 86篇 |
1978年 | 72篇 |
1977年 | 79篇 |
1975年 | 57篇 |
1974年 | 58篇 |
1973年 | 56篇 |
1972年 | 81篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
981.
Block KI Koch AC Mead MN Tothy PK Newman RA Gyllenhaal C 《Cancer treatment reviews》2007,33(5):407-418
PURPOSE: Much debate has arisen about whether antioxidant supplementation alters the efficacy of cancer chemotherapy. Some have argued that antioxidants scavenge the reactive oxygen species integral to the activity of certain chemotherapy drugs, thereby diminishing treatment efficacy. Others suggest antioxidants may mitigate toxicity and thus allow for uninterrupted treatment schedules and a reduced need for lowering chemotherapy doses. The objective of this study is to systematically review the literature in order to compile results from randomized trials that evaluate concurrent use of antioxidants with chemotherapy. DESIGN: MEDLINE, Cochrane, CinAhl, AMED, AltHealthWatch and EMBASE databases were searched. Only randomized, controlled clinical trials that reported survival and/or tumor response were included in the final tally. The literature searches were performed in duplicate following a standardized protocol. No meta-analysis was performed due to heterogeneity of tumor types and treatment protocols used in trials that met the inclusion criteria. RESULTS: Of 845 articles considered, 19 trials met the inclusion criteria. Antioxidants evaluated were: glutathione (7), melatonin (4), vitamin A (2), an antioxidant mixture (2), vitamin C (1), N-acetylcysteine (1), vitamin E (1) and ellagic acid (1). Subjects of most studies had advanced or relapsed disease. CONCLUSION: None of the trials reported evidence of significant decreases in efficacy from antioxidant supplementation during chemotherapy. Many of the studies indicated that antioxidant supplementation resulted in either increased survival times, increased tumor responses, or both, as well as fewer toxicities than controls; however, lack of adequate statistical power was a consistent limitation. Large, well-designed studies of antioxidant supplementation concurrent with chemotherapy are warranted. 相似文献
982.
Catherine Chen M.D. Laine H. Koch M.D. James E. Dice Pharm.D. Kimberly K. Dempsey M.P.A. P.A.‐C. Alan B. Moskowitz M.S. Myra L. Barnes‐Eley M.P.H. Thomas W. Hubbard M.D. J.D. Judith V. Williams M.D. 《Pediatric dermatology》2010,27(5):459-462
Abstract: Our objective was to compare the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. Forty children aged 1–11 years with clinically diagnosed tinea capitis were randomized to receive selenium sulfide shampoo 1% or ciclopirox shampoo 1% twice a week as adjuncts to an 8‐week course of ultramicronized griseofulvin dosed at 10–12 mg/kg/day. At weeks 2, 4, and 8, subjects returned to the clinic for evaluation and scalp cultures. Subjects then returned for follow‐up visits 4 weeks after completing treatment. Overall, by 8 weeks, 30 of 33 (90.9%) treated children demonstrated mycological cure. Selenium sulfide shampoo 1% and ciclopirox shampoo 1% were equally effective as adjunctive treatments for tinea capitis in children in our study. 相似文献
983.
984.
985.
986.
987.
988.
Wolfgang Mayer Jonas Mayr Felix Koch Ulrike Rechberger Werner Gasser Martin Hermann Angela Kempel Michael Edlinger Harald Schennach 《Transfusion》2023,63(8):1546-1553
Background
Extracorporeal photopheresis (ECP) treatment, mostly based on apheresis technology, is used for immunomodulation in various diseases such as cutaneous T-cell lymphoma, graft versus host disease and other (auto)immune disorders. The aim of this study was to collect high cell counts and purity in shorter procedure times using an ECP off-line system with an increased collection flow rate of 2 mL/min to a target volume of 200 mL buffy coat.Study design and methods
In this prospective study, data of routinely performed off-line photopheresis treatments were collected and analyzed at the Central Institute for Blood Transfusion & Department of Immunology (ZIB) of the Tirol Kliniken, to assess absolute cell counts and procedure times and to calculate collection efficiencies (CE2).Results
A total of 22 patients participated in this study. The processed blood volume was 4312 mL, the collection time 120 min, overall procedure time 157 min and the absolute cell counts of treated white blood cells (WBC) and mononuclear cells (MNC) were 5.0 and 4.3 × 109 respectively (median values). The calculated CE2 for WBC and MNC was 21.1% and 58.5%, the proportion of treated MNCs of the total number of MNCs present was 55.0%.Conclusion
The data presented in this study show high therapeutically effective cell counts collected with a high MNC purity within a shorter overall collection/procedure time due to an increased collection flow rate. 相似文献989.
Vitali Koch Leon D. Gruenewald Tatjana Gruber-Rouh Katrin Eichler David M. Leistner Scherwin Mahmoudi Christian Booz Simon Bernatz Tommaso D'Angelo Moritz H. Albrecht Leona S. Alizadeh Nour-Eldin A. Nour-Eldin Jan-Erik Scholtz Ibrahim Yel Thomas J. Vogl Winfried März Stefan E. Hardt Simon S. Martin 《Fundamental & clinical pharmacology》2023,37(3):519-529
Upcoming experimental and epidemiological data have identified the endogenous non-proteinogenic amino acid L-homoarginine (L-hArg) not only as a novel biomarker for cardiovascular disease but also as being directly involved in the pathogenesis of cardiac dysfunction. The association of low L-hArg levels with adverse cardiovascular events and mortality has proposed the idea of nutritional supplementation to rescue pathways inversely associated with cardiovascular health. Subsequent clinical and experimental studies contributed significantly to our knowledge of potential effects on the cardiorenal axis, acting either as a biomarker or a cardiovascular active agent. In this review article, we provide a comprehensive summary of the L-hArg metabolism, pathophysiological aspects, and current developments in the field of experimental and clinical evidence in favor of protective cardiovascular effects. Establishing a reliable biomarker to identify patients at high risk to die of cardiovascular disease represents one of the main goals for tackling this disease and providing individual therapeutic guidance. 相似文献
990.